164 related articles for article (PubMed ID: 18704362)
1. [Active immunotherapy of urologic malignancies and tumor-mediated immunosuppression].
Kübler H; Gschwend JE
Urologe A; 2008 Sep; 47(9):1122-7. PubMed ID: 18704362
[TBL] [Abstract][Full Text] [Related]
2. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
4. Present status and future perspective of peptide-based vaccine therapy for urological cancer.
Obara W; Kanehira M; Katagiri T; Kato R; Kato Y; Takata R
Cancer Sci; 2018 Mar; 109(3):550-559. PubMed ID: 29345737
[TBL] [Abstract][Full Text] [Related]
5. Reversal of tumor-mediated immunosuppression.
Vieweg J; Su Z; Dahm P; Kusmartsev S
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):727s-732s. PubMed ID: 17255301
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
9. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
[TBL] [Abstract][Full Text] [Related]
10. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
Bracarda S; Altavilla A; Hamzaj A; Sisani M; Marrocolo F; Del Buono S; Danielli R
Semin Oncol; 2015 Jun; 42(3):495-505. PubMed ID: 25965369
[TBL] [Abstract][Full Text] [Related]
11. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
13. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
14. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of action of intravesical BCG. Biological bases and clinical applicability.].
Carballido JA; Rodríguez Monsalve M
Arch Esp Urol; 2018 May; 71(4):358-375. PubMed ID: 29745925
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
Surolia I; Gulley J; Madan RA
Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Bellmunt J; Ribas A
Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
[No Abstract] [Full Text] [Related]
18. High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
Muhitch JB; Schwaab T
Immunotherapy; 2014; 6(9):955-8. PubMed ID: 25341116
[No Abstract] [Full Text] [Related]
19. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
Clark PE
Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523
[No Abstract] [Full Text] [Related]
20. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]